{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:26Z","timestamp":1792068866844,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022789","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jacadv.2025.102122","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:49:46Z","timestamp":1757555386000},"page":"102122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"P2","title":["Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1016","volume":"4","author":[{"given":"Maria G.","family":"Crespo-Leiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Ebede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Drachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.102122_bib1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2025.102122_bib2","series-title":"VYNDAQEL and VYNDAMAX highlights of prescribing information","year":"2023"},{"key":"10.1016\/j.jacadv.2025.102122_bib3","series-title":"Vyndaqel (tafamidis) summary of product characteristics","year":"2025"},{"key":"10.1016\/j.jacadv.2025.102122_bib4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102122_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102122_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102122_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2019.1643714","article-title":"A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy","volume":"26","author":"Huber","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.jacadv.2025.102122_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/DHPS.S338577","article-title":"Updated evaluation of the safety, efficacy and tolerability of tafamidis in the treatment of hereditary transthyretin amyloid polyneuropathy","volume":"15","author":"Falc\u00e3o de Campos","year":"2023","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.jacadv.2025.102122_bib9","article-title":"Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system","volume":"14","author":"Wu","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacadv.2025.102122_bib10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ejhpharm-2018-001823","article-title":"Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review","volume":"27","author":"Crist\u00f3bal Guti\u00e9rrez","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jacadv.2025.102122_bib11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"31","author":"Garcia-Pavia","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacadv.2025.102122_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","article-title":"Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey","volume":"3","author":"Nativi-Nicolau","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2025.102122_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacadv.2025.102122_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102122_bib15","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102122_bib16","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102122_bib17","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102122_bib18","first-page":"2008","article-title":"Expansion of the national amyloidosis centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102122_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033478","article-title":"Outcomes in cardiac transthyretin amyloidosis and association with New York heart association class: real-world data","volume":"13","author":"M\u00fcller","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.102122_bib20","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102122_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25005472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25005472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:02:37Z","timestamp":1764043357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25005472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2772963X25005472"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102122","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102122"}}